PGT Raises £3.8 Million in Series A Funding; Appoints Mel N. Kronick Chief Executive Officer

February 19, 2008

Cambridge, UK – 19 February 2008 – Population Genetics Technologies Limited (‘PGT’), a privately-held company focused on creating new paradigms for performing large-scale population genetics studies, today announced that it has raised £3.8 million in a first round of venture funding.  The venture financing was provided by Auriga Partners, Noble Fund Managers, and Compass Genetics Investors LLC (the founders of PGT: Drs. Sydney Brenner, Sam Eletr and Philip Goelet).

Read more

“Our technology enables the rapid discovery of gene variants characteristic of a particular disorder or a specific drug response."

Dr. Sydney Brenner – Nobel Laureate and co-founder of Population Genetics Technologies Ltd

Read more.

PGT Awarded NHS Grant to Fund Pharmacogenetic Study

PGT has been awarded a grant from the National Institute for Health Research (NIHR) as part of the Institute’s Invention for Innovation (i4i) Programme.

Read More.